Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Eric G. Bluemn, Ilsa M. Coleman, Jared M. Lucas, et al.
Cancer Cell (2017) Vol. 32, Iss. 4, pp. 474-489.e6
Open Access | Times Cited: 639

Showing 26-50 of 639 citing articles:

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Loredana Puca, Katie Gavyert, Verena Sailer, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 484
Open Access | Times Cited: 160
N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer
Adeline Berger, Nicholas J. Brady, Rohan Bareja, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 9, pp. 3924-3940
Open Access | Times Cited: 159
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer
Himisha Beltran, Alessandro Romanel, Vincenza Conteduca, et al.
Journal of Clinical Investigation (2020) Vol. 130, Iss. 4, pp. 1653-1668
Open Access | Times Cited: 159
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
Fanying Tang, Duo Xu, Shangqian Wang, et al.
Science (2022) Vol. 376, Iss. 6596
Open Access | Times Cited: 157
Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells
Takeshi Namekawa, Kazuhiro Ikeda, Kuniko Horie‐Inoue, et al.
Cells (2019) Vol. 8, Iss. 1, pp. 74-74
Open Access | Times Cited: 151
2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
Arnaud Blomme, Catriona A. Ford, Ernest Mui, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 147
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Yundong He, Weidong Xu, Yu‐Tian Xiao, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 125
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
Sylvan C. Baca, David Y. Takeda, Ji-Heui Seo, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 124
Molecular events in neuroendocrine prostate cancer development
Yong Wang, Yu Wang, Xinpei Ci, et al.
Nature Reviews Urology (2021) Vol. 18, Iss. 10, pp. 581-596
Open Access | Times Cited: 121
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer
Alastair Davies, Shaghayegh Nouruzi, Dwaipayan Ganguli, et al.
Nature Cell Biology (2021) Vol. 23, Iss. 9, pp. 1023-1034
Open Access | Times Cited: 116
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
Silke Gillessen, Alberto Bossi, Ian D. Davis, et al.
European Journal of Cancer (2023) Vol. 185, pp. 178-215
Open Access | Times Cited: 100
Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance
Su Deng, Choushi Wang, Yunguan Wang, et al.
Nature Cancer (2022) Vol. 3, Iss. 9, pp. 1071-1087
Open Access | Times Cited: 87
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
Lina Merkens, Verena Sailer, Davor Lessel, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 84
Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models
Delphine Lissa, Nobuyuki Takahashi, Parth Desai, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 72
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer
Hanling Wang, Ni Li, Qiuli Liu, et al.
Cancer Cell (2023) Vol. 41, Iss. 7, pp. 1345-1362.e9
Closed Access | Times Cited: 69
Numb/Parkin-directed mitochondrial fitness governs cancer cell fate via metabolic regulation of histone lactylation
Yuman He, Zhongzhong Ji, Yiming Gong, et al.
Cell Reports (2023) Vol. 42, Iss. 2, pp. 112033-112033
Open Access | Times Cited: 68
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 57
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
Vipul Bhatia, Nikhil Kamat, Tiffany E. Pariva, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 55
The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity
Alastair Davies, Amina Zoubeidi, Himisha Beltran, et al.
Cancer Discovery (2023) Vol. 13, Iss. 8, pp. 1771-1788
Closed Access | Times Cited: 50
Effects and Mechanisms of Luteolin, a Plant-Based Flavonoid, in the Prevention of Cancers via Modulation of Inflammation and Cell Signaling Molecules
Saleh A. Almatroodi, Ahmad Almatroudi, Hajed Obaid Alharbi, et al.
Molecules (2024) Vol. 29, Iss. 5, pp. 1093-1093
Open Access | Times Cited: 16
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product
Avanish Mishra, Shih‐Bo Huang, Taronish D. Dubash, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Bram De Laere, Steffi Oeyen, Markus Mayrhofer, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 6, pp. 1766-1773
Open Access | Times Cited: 145
Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis
Timothy O. Adekoya, Ricardo M. Richardson
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 12, pp. 4449-4449
Open Access | Times Cited: 134
Integrative epigenetic taxonomy of primary prostate cancer
Suzan Stelloo, Ekaterina Nevedomskaya, Yongsoo Kim, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 131
Tumor fraction in cell-free DNA as a biomarker in prostate cancer
Atish D. Choudhury, Lillian Werner, Edoardo Francini, et al.
JCI Insight (2018) Vol. 3, Iss. 21
Open Access | Times Cited: 128

Scroll to top